Themis Medicare Share Price Target For Tomorrow, Next Week & Next Month
Themis Medicare Limited | |||
 | Price: ₹99.08 (-0.77%) | ||
| 52 Week Low: ₹98.00 52 Week High: ₹317.00 | |||
| Market Capital: 1,962.75 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Themis Medicare Stock Comparison: Themis Medicare vs Hester Biosciences | Themis Medicare vs IOL Chemicals and Pharmaceuticals Limited | Themis Medicare vs Solara Active Pharma Sciences Limited | Themis Medicare vs Amrutanjan Health Care | Themis Medicare vs TTK Healthcare | Themis Medicare vs Suven Life Sciences | |||
Share Price HistoryTHEMISMED FinancialsTomorrow TargetYearly TargetsDividend HistoryNo BonusSplit History
Show Table of Contents
Themis Medicare Recent Performance
Over the past 445 trading days, the value of Themis Medicare's stock has lost ₹46.02 (-31.72%). On 07 Nov 2023, one share was worth ₹145.10 and by 29 Aug 2025, the value dropped to ₹99.08. During this period it created a highest high of ₹317.00 and lowest low of ₹98.00.
Themis Medicare Share Price Target - Tomorrow
| Level | Value | Analysis |
|---|---|---|
| Tomorrow Target 3 | 114.48 (+15.54%) | Price Action: 30 Jul 2025 High |
| Tomorrow Target 2 | 111.94 (+12.97%) | Price Action: Chart |
| Tomorrow Target 1 | 110.83 (+11.85%) | Price Action: 28 Jul 2025 Low |
| Current Price | 99.08 | Themis Medicare's share price as of 29 Aug 2025 |
| Stop Loss 1 | 87.77 (-11.42%) | Price Action: Chart |
| Stop Loss 2 | 86.89 (-12.31%) | Price Action: Chart |
| Stop Loss 3 | 85.33 (-13.88%) | Price Action: Chart |
Summary
29 Aug 2025: Themis Medicare finished the day at ₹99.08, losing ₹-0.77 (-0.77%) in 1 day.
Our analysis for tomorrow predicts a potential movement of -13.88% to 15.54% with:
- Target prices: ₹110.83 to ₹114.48
- Support levels: ₹87.77 to ₹85.33
- Recent high: ₹100.41
- Recent low: ₹98.00
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Themis Medicare Share Price Target - Next Week
| Level | Value | Analysis |
|---|---|---|
| Next Week Target 3 | 103.99 (+4.95%) | Price Action: 05 Aug 2025 High |
| Next Week Target 2 | 102.82 (+3.77%) | Price Action: 18 Aug 2025 Low |
| Next Week Target 1 | 100.99 (+1.92%) | Fibonacci Extension Level 23.60% |
| Current Price | 99.08 | Themis Medicare's share price as of 29 Aug 2025 |
| Stop Loss 1 | 98.41 (-0.68%) | Price Action: Aug 2025 Low |
| Stop Loss 2 | 97.43 (-1.67%) | Price Action: Chart |
| Stop Loss 3 | 95.72 (-3.4%) | Fibonacci Retracement Level 28.20% |
Weekly Target Summary
For next week, our analysis suggests a potential movement range of -3.39% to 4.96% with:
- Upper targets: ₹100.99 to ₹103.99
- Support levels: ₹98.41 to ₹95.72
Themis Medicare Share Price Target - Next Month
| Level | Value | Analysis |
|---|---|---|
| Next Month Target 3 | 117.49 (+18.57%) | Fibonacci Extension Level 23.60% |
| Next Month Target 2 | 116.16 (+17.23%) | Price Action: 24 Jul 2025 Low |
| Next Month Target 1 | 114.48 (+15.54%) | Price Action: 30 Jul 2025 High |
| Current Price | 99.08 | Themis Medicare's share price as of 29 Aug 2025 |
| Stop Loss 1 | 94.9 (-4.22%) | Price Action: Chart |
| Stop Loss 2 | 93.95 (-5.18%) | Price Action: Chart |
| Stop Loss 3 | 92.26 (-6.89%) | Price Action: Chart |
Monthly Target Summary
Looking ahead to next month, technical analysis indicates:
- Potential price movement: -6.88% to 18.58% with:
- Target range: ₹114.48 to ₹117.49
- Support levels: ₹94.9 to ₹92.26
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
